←Back to Expert Scholars
Translational Medicine / 转化医学MDS, Clinical Trials
Alan List
MD
🏢Moffitt Cancer Center🌐USA
Former President and CEO
85
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Alan List pioneered lenalidomide for del(5q) MDS and led Moffitt's MDS program for years. He has contributed to multiple MDS drug development programs including luspatercept and novel agents. His work defined targeted therapy for del(5q) MDS.
Share:
🧪Research Fields 研究领域
lenalidomide MDS
del(5q) MDS
MDS drug development
luspatercept
Moffitt MDS program
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Alan List 的研究动态
Follow Alan List's research updates
留下邮箱，当我们发布与 Alan List（Moffitt Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment